Like Leadscope, Inc.

closed 11/15/2019 via BusinessWire

Instem, acquired Leadscope, Inc.

See 160 Comparable Transactions
synopsis: Instem, a leading provider of IT solutions to the global life sciences market, announced that it has acquired Leadscope, a company that builds a chemoinformatics platform. Using Leadscope, researchers have integrated access to chemistry-based data mining, visualization and advanced informatics techniques.
buyer: Instem (AIM:INS:$30.83)
Instem is a leading supplier of IT applications to the early development healthcare market delivering compelling solutions for data collection, management and analysis across the R&D continuum. Instem applications are in use by customers worldwide. "
 target: Leadscope, Inc.
Leadscope builds a chemoinformatics platform. As a suite of tools, researchers have integrated access to chemistry-based data mining, visualization and advanced informatics techniques (prediction tools, scaffold generators, etc.).
price ($mm)
$4.10
rev ($mm)
$2
EBITDA ($mm)
$0
EV / rev
2.4x
EV / EBITDA
11.5x
announced 1/24/2020 via GlobeNewswire

Predictive Oncology Inc., will acquire Quantitative Medicine

See 202 Comparable Transactions
synopsis: Predictive Oncology Inc. , a knowledge-driven company focused on applying artificial intelligence to personalized medicine and drug discovery, is to acquire Quantitative Medicine, a biomedical analytics and computational biology company that has developed a novel, computational drug discovery platform called CoRE.
buyer: Predictive Oncology Inc. (POAI:$1.38)
Predictive Oncology Inc. is a knowledge-driven company focused on applying artificial intelligence to personalized medicine and drug discovery. Predictive Oncology operates through five segments which contain four subsidiaries; Helomics, TumorGenesis, Skyline Medical and Skyline Europe. "
 target: Quantitative Medicine
Quantitative Medicine is a biomedical analytics and computational biology company that has developed a novel, computational drug discovery platform called CoRE. CoRE is designed to dramatically reduce the time, cost and financial risk of discovering new therapeutic drugs.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 3/2/2016 via Company Press Release

C4X Discovery, acquired Adorial

See 157 Comparable Transactions
synopsis: C4X Discovery, a company that aims to become the world’s most productive drug discovery and development company, has acquired Adorial, a privately held drug discovery company with a proprietary genetic technology platform for the identification of novel drug targets.
buyer: C4X Discovery (AIM:C4XD:$0.44)
C4X Discovery aims to become the world’s most productive drug discovery and development company by exploiting cutting-edge technologies to design and create best-in-class drug candidates. "
 target: Adorial
Adorial's key genetic technology, Taxonomy3® is a novel in silico platform technology that utilises proprietary ground-breaking mathematical algorithms to perform complex multivariate analysis of genetic data.
price ($mm)
$2.36
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 9/3/2012 via BusinessWire

CLC bio A/S, acquired Molegro

See 183 Comparable Transactions
synopsis: CLC bio announced the acquisition of Molegro, a specialized software company focusing on molecular docking, including prediction and analysis of protein-ligand interactions, screening of compound databases for activities against a receptor, and determination of molecule similarity.
buyer: CLC bio A/S
CLC bio is the world's leading bioinformatics solution provider and the only one that provides both desktop and server software seamlessly integrated and optimized for best performance. The company is headquarted in Aarhus, Denmark. "
 target parent: Østjysk Innovation A/S
target: Molegro
Founded in 2005, Molegro is a specialized software company focusing on molecular docking, including prediction and analysis of protein-ligand interactions, screening of compound databases for activities against a receptor, and determination of molecule similarity.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 4/17/2019 via BNC Analysis

Emerson, acquired Bio-G

See 32 Comparable Transactions
synopsis: Emerson, a global technology and engineering company, has acquired Bioproduction Group (Bio-G), a leader in simulation, modeling, and scheduling software for biomanufacturing. Bio-G's high quality modeling and scheduling software solutions drive day-to-day, tactical and strategic decision making for leading biopharmaceutical manufacturers.
buyer: Emerson (EMR:$18,061.00)
Emerson is a global technology and engineering company providing innovative solutions for customers in industrial, commercial, and residential markets. They help process, hybrid, and discrete manufacturers maximize production and protect the environment. "
 target: Bio-G
Bioproduction Group (Bio-G) is a leader in simulation, modeling, and scheduling software for biomanufacturing. Bio-G's high quality modeling and scheduling software solutions drive day-to-day, tactical and strategic decision making for some of the world's largest biopharmaceutical manufacturers.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 3/13/2012 via BusinessWire

Certara, will acquire Simcyp Limited

See 240 Comparable Transactions
synopsis: Certara has announced the completion of its acquisition of UK-based Simcyp Limited. Simcyp is a leading research company providing a modeling and simulation platform for predicting the fate of drugs in virtual populations, including pediatric populations.
buyer parent: Vector Capital
buyer: Certara
Certara™ is dedicated to improving human health through a broad spectrum of software products and services, from molecular discovery through clinical development, with special focus on supporting translational approaches to drug development. "
 target parent: Fusion IP plc
target: Simcyp Limited
Simcyp provides platforms for the modeling and simulation of pharmacokinetics and pharmacodynamics in virtual human populations and virtual laboratory animals (rat, dog and mouse).
price ($mm)
$32
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 11/3/2008 via BusinessWire

Tripos, Inc., acquired Pharsight Corporation

See 240 Comparable Transactions
synopsis: Tripos International, the leading provider of drug discovery informatics products and services, today announced that it has completed the acquisition of Pharsight Corporation, a leader in software, strategic and regulatory services designed to optimize clinical drug development.
buyer parent: Vector Capital
buyer: Tripos, Inc.
Tripos combines leading-edge technology and innovative science to deliver consistently superior chemistry-research products and services for the biotechnology, pharmaceutical and other life science industries. "
 target: Pharsight Corporation
Pharsight Corporation develops and markets integrated products and services that enable pharmaceutical and biotechnology companies to achieve significant and enduring improvements in the development and use of therapeutic products.
price ($mm)[EV]
$52 [$36]
rev ($mm)
$28
EBITDA ($mm)
$2
EV / rev
1.4x
EV / EBITDA
17.8x
closed 5/1/2006 via BusinessWire

PerkinElmer, Inc., acquired Spectral Genomics, Inc.

See 240 Comparable Transactions
synopsis: PerkinElmer, Inc., a global technology leader in Health Sciences and Photonics, today announced the acquisition of the assets of Spectral Genomics, Inc., a leader in molecular karyotyping technology used to evaluate chromosomal abnormalities. Terms of the deal were not disclosed.
buyer: PerkinElmer, Inc. (PKI:$2,209.40)
PerkinElmer, Inc. is a global technology leader focused in the following businesses - Life and Analytical Sciences, Optoelectronics and Fluid Sciences. "
 target: Spectral Genomics, Inc.
Spectral Genomics' array products and analysis software help pharmaceutical, biotechnology, cytogenetic and clinical researchers identify chromosomal abnormalities related to the study of cancer and pre- and post-natal genetic disorders.
price ($mm)
$12
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 4/2/2020 via BusinessWire

Simulations Plus, Inc., acquired Lixoft

See 164 Comparable Transactions
synopsis: Simulations Plus, Inc., a leading provider of simulation and modeling software for pharmaceutical discovery and development, has acquired Lixoft of Paris, France. Lixoft designs software solutions based on scientific breakthroughs to reduce the cost and increase the success rate of new drug development.
buyer: Simulations Plus, Inc. (SLP:$35.84)
Simulations Plus is a premier developer of drug discovery and development software and is a provider of preclinical and clinical pharmacometric consulting services for regulatory submissions. The company also provides quantitative systems pharmacology models for liver-related injury and disease. "
 target: Lixoft
Paris-based Lixoft designs software solutions based on scientific breakthroughs to reduce the cost and increase the success rate of new drug development. The company's Monolix Suite is a leading provider of population PKPD (Pharmacokinetic/Pharmacodynamic) modeling for pharmacometricians.
price ($mm)
$11
rev ($mm)
$4
EBITDA ($mm)
EV / rev
4.7x
EV / EBITDA
closed 9/13/2018 via BusinessWire

Certara, acquired Pirana Software

See 83 Comparable Transactions
synopsis: Certara, the global leader in model-informed drug development, regulatory science, market access and real-world evidence solutions, announced that it has acquired Pirana, a widely used product for connecting and organizing pharmacometric modeling results as well as providing interfaces to a range of software tools used in pharmacometrics modeling.
buyer parent: Arsenal Capital Partners
buyer: Certara
Certara enables superior drug development and patient care decision-making through model-informed drug development, regulatory science, real-world evidence solutions and knowledge integration. "
 target: Pirana Software
Pirana is a widely used product for connecting and organizing pharmacometric modeling results as well as providing interfaces to a range of software tools used in pharmacometrics modeling.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 6/1/2017 via BusinessWire

Simulations Plus, Inc., acquired DILIsym Services, Inc.

See 157 Comparable Transactions
synopsis: Simulations Plus, Inc., a leading provider of simulation and modeling software for pharmaceutical discovery and development, announced that it has acquired DILIsym Services, Inc, the leading provider of drug-induced liver injury simulation software and related consulting services to the pharmaceutical industry.
buyer: Simulations Plus, Inc. (SLP:$35.84)
Simulations Plus, Inc. is a premier developer of groundbreaking drug discovery and development simulation and modeling software that is licensed to and used in the conduct of drug research by major pharmaceutical, biotechnology, agrochemical, and food industry companies worldwide. "
 target: DILIsym Services, Inc.
DILIsym Services, Inc. was founded in 2015 in Research Triangle Park, North Carolina, and is the leading provider of drug-induced liver injury simulation software and related consulting services to the pharmaceutical industry.
price ($mm)[EV]
$4.50 [$5.00]
rev ($mm)
$3
EBITDA ($mm)
EV / rev
3.3x
EV / EBITDA
closed 1/8/2013 via Yahoo, Inc.

Elsevier B.V., acquired Aureus Sciences

See 247 Comparable Transactions
synopsis: Elsevier announced the acquisition of Aureus Sciences, a Paris, France based privately held company that provides databases and information tools to pharmaceutical and biotech companies. Aureus Sciences gathers unique and high quality quantitative biological activity data for major therapeutic drug targets.
buyer parent: Reed Elsevier
buyer: Elsevier B.V.
Elsevier is a world-leading provider of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet and Cell, and close to 20,000 book titles. "
 target: Aureus Sciences
Aureus Sciences provides scientific databases and software applications for researchers involved in the drug discovery and development process.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 9/2/2014 via BusinessWire

Cognigen Corporation merged with Simulations Plus, Inc.,

See 133 Comparable Transactions
synopsis: Simulations Plus, Inc., a leading provider of simulation and modeling software for pharmaceutical discovery and development, announced that the Agreement and Plan of Merger with Cognigen Corporation has been closed. Cognigen Corporation was founded in 1993 and has grown to become one of the leading providers of clinical trial data analysis.
buyer: Simulations Plus, Inc. (SLP:$35.84)
Simulations Plus, Inc., is a premier developer of groundbreaking drug discovery and development simulation and modeling software that is licensed to and used in the conduct of drug research by major pharmaceutical, biotechnology, agrochemical, and food industry companies worldwide. "
 target: Cognigen Corporation
Cognigen Corporation is one of the leading providers of clinical trial data analysis. The company provides analysis and reports that are tailored to the expectations of regulatory agencies so that reports are submitted in a manner that minimizes follow-up questions from regulators.
price ($mm)
$5.20
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 2/6/2014 via BNC Analysis

Berry Consultants, LLC, will purchase FACTS from Tessella Ltd.

See 133 Comparable Transactions
synopsis: Berry Consultants, a statistical consulting company specializing in the Bayesian approach to medical statistics, has reached an agreement with Tessella to acquire 100% ownership of FACTS. FACTS (Fixed and Adaptive Clinical Trial Simulator) is the most powerful, versatile, and fastest clinical trial simulation tool on the market.
buyer: Berry Consultants, LLC
Berry Consultants is a statistical consulting company specializing in the Bayesian approach to medical statistics, an approach that is radically changing the way research is done throughout both device and drug development. "
 seller: Tessella Ltd.
FACTS (Fixed and Adaptive Clinical Trial Simulator) is the most powerful, versatile, and fastest clinical trial simulation tool on the market. It allows biostatisticians and clinical teams to rapidly design and compare innovative, advanced, clinical trial designs.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 1/8/2014 via PR Newswire

Evidera, acquired Archimedes, Inc.

See 171 Comparable Transactions
synopsis: Symphony Technology Group (STG), a technology and services-focused private equity firm, and Evidera, a leading provider of evidence-based solutions for the healthcare industry, announced the acquisition of Archimedes, a San Francisco-based healthcare modeling company and wholly owned subsidiary of Kaiser Permanente.
buyer parent: Symphony Technology Group
buyer: Evidera
Evidera provides health economics, outcomes research, market access, data analytics and epidemiology services. Their research and consulting services are driven by world-class science and thought leadership and leverage a unique combination of capabilities. "
 target parent: Kaiser Permanente
target: Archimedes, Inc.
Archimedes is a healthcare modeling and analytics organization. With the Archimedes Model at its core, the company enables people to combine real-world healthcare data and simulation data to create compelling and actionable evidence used in individual healthcare decision making.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 6/27/2013 via PR Newswire

Temis Text Intelligence, acquired i3 Analytics

See 78 Comparable Transactions
synopsis: TEMIS, the leading provider of Semantic Content Enrichment solutions for the Enterprise, announced that they have acquired the US-based i3 Analytics. i3 Analytics provides the award-winning Biopharma Navigator, a Software-as-a-Service platform that charts the biopharma landscape based on Life Sciences open data.
buyer: Temis Text Intelligence
In order to develop and market innovative Text Mining Solutions, TEMIS was founded in September 2000 by a team of managers, researchers and consultants from IBM. This skilled team had earlier developed and distributed IBM Text Mining solutions worldwide "
 target: i3 Analytics
i3 Analytics is a provider of advanced data analytics and visualization technologies. Their Biopharma Navigator is an analytics tool that allow users to map clinical trials landscapes, scan the horizon for the latest news, and stay current on what researchers are doing.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 4/22/2009 via BusinessWire

Phase Forward, acquired Waban Software

See 133 Comparable Transactions
synopsis: Phase Forward, a leading provider of data management solutions for clinical trials and drug safety, announced that it has acquired privately held Waban Software, a leading provider of platform solutions for the automation and compliance of clinical data analysis and reporting, for $14 million in cash.
buyer: Phase Forward (PFWD:$0.00)
Phase Forward is a leading provider of integrated data management solutions for clinical trials and drug safety. The company offers proven solutions for electronic data capture, clinical data management and clinical data analysis and reporting automation and compliance. "
 target: Waban Software
Waban Software provides solutions that enable pharmaceutical and biotechnology companies to capture, integrate, manage and analyze life-sciences and clinical trial data.
price ($mm)
$12
rev ($mm)
$4
EBITDA ($mm)
EV / rev
3.5x
EV / EBITDA
closed 11/12/2008 via BusinessWire

JNetDirect, Inc., acquired Sunergia Group, Inc.

See 332 Comparable Transactions
synopsis: JNetDirect Inc. announced the acquisition of Sunergia Group Inc. and its better known operating unit, Sunergia Medical (www.sunergiamedical.com). Sunergia, a privately owned supplier of software and lab equipment to the biotech market, will now be renamed JNetDirect Biosciences.
buyer: JNetDirect, Inc.
JNetDirect is an innovative leader in software products for improving our customer's connectivity, integration, management and security to their data resources. Over 3000 companies rely on JNetDirect software to provide critical components for their applications and development environments. "
 target: Sunergia Group, Inc.
Founded in 2002, Sunergia has built a customer base that includes hundreds of the major university research labs, national research facilities (NIH, NIA, NIMH and NCI) and leading pharmaceutical and biotech companies.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 8/25/2005 via BusinessWire

Phase Forward, acquired Lincoln Technologies, Inc.

See 332 Comparable Transactions
synopsis: Phase Forward, a leading provider of data management solutions for clinical trials and drug safety, announced that it has completed the previously announced acquisition of privately held Lincoln Technologies, Inc. in an all-cash transaction valued at $11 million, plus up to an additional $6 million based on achievement of certain financial targets.
buyer: Phase Forward (PFWD:$0.00)
Phase Forward is a leading provider of integrated data management solutions for clinical trials and drug safety. The company offers proven solutions for electronic data capture, clinical data management and clinical data analysis and reporting automation and compliance. "
 target: Lincoln Technologies, Inc.
Lincoln Technologies, Inc. is a software technology and services company that delivers advanced application solutions for pharmaceutical industry drug development. Lincoln's business is focused on pharmacovigilance, data standardization, and safety signal detection and monitoring.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 6/12/2014 via Company Press Release

Wiley, acquired SimBioSys Inc.

See 341 Comparable Transactions
synopsis: John Wiley & Sons, Inc., a global provider of knowledge and knowledge-enabled solutions that improve outcomes in research, professional practice, and education, announced that it has acquired SimBioSys Inc., a provider of scientific software tools that facilitate the drug discovery process.
buyer: Wiley (NYSE:JW.A:$1,848.05)
Wiley is a global provider of knowledge and knowledge-enabled services that improve outcomes in areas of research, professional practice, and education. "
 target: SimBioSys Inc.
SimBioSys is a recognized leader in the field of rational drug discovery software. Providing a wide range of software solutions, the company is focused on the development of scientific tools to facilitate the drug discovery process.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
Pages:  
closed 11/15/2019 via BusinessWire

Instem, acquired Leadscope, Inc.

See 160 Comparable Transactions
synopsis: Instem, a leading provider of IT solutions to the global life sciences market, announced that it has acquired Leadscope, a company that builds a chemoinformatics platform. Using Leadscope, researchers have integrated access to chemistry-based data mining, visualization and advanced informatics techniques.
buyer: Instem (AIM:INS:$30.83)
Instem is a leading supplier of IT applications to the early development healthcare market delivering compelling solutions for data collection, management and analysis across the R&D continuum. Instem applications are in use by customers worldwide. "
 target: Leadscope, Inc.
Leadscope builds a chemoinformatics platform. As a suite of tools, researchers have integrated access to chemistry-based data mining, visualization and advanced informatics techniques (prediction tools, scaffold generators, etc.).
price ($mm)
$4.10
rev ($mm)
$2
EBITDA ($mm)
$0
EV / rev
2.4x
EV / EBITDA
11.5x
closed 11/15/2019 via BusinessWire

Instem, acquired Leadscope, Inc.

See 160 Comparable Transactions
synopsis: Instem, a leading provider of IT solutions to the global life sciences market, announced that it has acquired Leadscope, a company that builds a chemoinformatics platform. Using Leadscope, researchers have integrated access to chemistry-based data mining, visualization and advanced informatics techniques.
buyer: Instem (AIM:INS:$30.83)
Instem is a leading supplier of IT applications to the early development healthcare market delivering compelling solutions for data collection, management and analysis across the R&D continuum. Instem applications are in use by customers worldwide. "
 target: Leadscope, Inc.
Leadscope builds a chemoinformatics platform. As a suite of tools, researchers have integrated access to chemistry-based data mining, visualization and advanced informatics techniques (prediction tools, scaffold generators, etc.).
price ($mm)
$4.10
rev ($mm)
$2
EBITDA ($mm)
$0
EV / rev
2.4x
EV / EBITDA
11.5x
closed 9/5/2016 via Company Press Release

Instem, acquired Notocord

See 308 Comparable Transactions
synopsis: Instem, a leading provider of IT solutions to the global early development healthcare market, announced today that it has acquired NOTOCORD. NOTOCORD provides software solutions for data acquisition and analysis in preclinical studies and is a recognized leader in cardiovascular, respiratory, electrophysiology and nervous system research areas.
buyer: Instem (AIM:INS:$30.83)
Instem is a leading supplier of IT applications to the early development healthcare market delivering compelling solutions for data collection, management and analysis across the R&D continuum. Instem applications are in use by customers worldwide. "
 target: Notocord
Notocord, Inc. designs software and provides data acquisition, analysis, as well as reporting solutions. Their solutions are fit for preclinical R&D, including efficacy testing, early safety, regulatory safety pharmacology and toxicology studies.
price ($mm)
$2.25
rev ($mm)
$3
EBITDA ($mm)
EV / rev
2.0x
EV / EBITDA
closed 5/31/2016 via BusinessWire

Instem LSS Ltd, acquired Samarind Limited

See 90 Comparable Transactions
synopsis: Instem, a leading provider of IT solutions to the global early development healthcare market, announced that it has acquired the UK-headquartered Samarind organization to help bring scalability and next generation capabilities to the increasingly complex global regulatory environment.
buyer: Instem LSS Ltd (AIM:INS:$30.83)
Instem is a leading supplier of IT applications to the early development healthcare market delivering compelling solutions for data collection, management and analysis across the R&D continuum. Instem applications are in use by customers worldwide. "
 target: Samarind Limited
Samarind provides database software solutions to a wide range of businesses, with particular focus on Life Sciences. Their flagship product, Samarind RMS, is an award-winning database system for regulatory affairs professionals in the pharmaceutical and medical devices industries.
price ($mm)
$3.12
rev ($mm)
$2
EBITDA ($mm)
EV / rev
2.1x
EV / EBITDA
closed 5/13/2013 via BNC Analysis

Instem LSS Ltd, acquired Logos Technologies

See 294 Comparable Transactions
synopsis: Instem plc announced the acquisition of the entire issued share capital of Logos Holdings Limited along with its subsidiaries Logos EDC Solutions Limited and Logos Technologies Inc. The acquisition represents a strategic move by Instem into the early phase clinical market.
buyer: Instem LSS Ltd (AIM:INS:$30.83)
Instem is a leading supplier of IT applications to the early development healthcare market delivering compelling solutions for data collection, management and analysis across the R&D continuum. Instem applications are in use by customers worldwide. "
 target: Logos Technologies
Logos Technologies is one of the early pioneers in providing world class solutions to pharmaceutical, contract research organisations and biotechnology companies with electronic data capture (EDC) and clinical management solutions needed to accelerate pharmaceutical research and development.
price ($mm)
$0.84
rev ($mm)
$1
EBITDA ($mm)
$0
EV / rev
6.3x
EV / EBITDA
69.5x
closed 11/15/2019 via BusinessWire

Instem, acquired Leadscope, Inc.

See 160 Comparable Transactions
synopsis: Instem, a leading provider of IT solutions to the global life sciences market, announced that it has acquired Leadscope, a company that builds a chemoinformatics platform. Using Leadscope, researchers have integrated access to chemistry-based data mining, visualization and advanced informatics techniques.
buyer: Instem (AIM:INS:$30.83)
Instem is a leading supplier of IT applications to the early development healthcare market delivering compelling solutions for data collection, management and analysis across the R&D continuum. Instem applications are in use by customers worldwide. "
 target: Leadscope, Inc.
Leadscope builds a chemoinformatics platform. As a suite of tools, researchers have integrated access to chemistry-based data mining, visualization and advanced informatics techniques (prediction tools, scaffold generators, etc.).
price ($mm)
$4.10
rev ($mm)
$2
EBITDA ($mm)
$0
EV / rev
2.4x
EV / EBITDA
11.5x
closed 9/5/2016 via Company Press Release

Instem, acquired Notocord

See 308 Comparable Transactions
synopsis: Instem, a leading provider of IT solutions to the global early development healthcare market, announced today that it has acquired NOTOCORD. NOTOCORD provides software solutions for data acquisition and analysis in preclinical studies and is a recognized leader in cardiovascular, respiratory, electrophysiology and nervous system research areas.
buyer: Instem (AIM:INS:$30.83)
Instem is a leading supplier of IT applications to the early development healthcare market delivering compelling solutions for data collection, management and analysis across the R&D continuum. Instem applications are in use by customers worldwide. "
 target: Notocord
Notocord, Inc. designs software and provides data acquisition, analysis, as well as reporting solutions. Their solutions are fit for preclinical R&D, including efficacy testing, early safety, regulatory safety pharmacology and toxicology studies.
price ($mm)
$2.25
rev ($mm)
$3
EBITDA ($mm)
EV / rev
2.0x
EV / EBITDA
closed 5/20/2011 via PR Newswire

PRA International, acquired Kinship Technologies Pvt. Ltd.

See 308 Comparable Transactions
synopsis: PRA International has acquired Kinship Technologies, a Chennai, India-based software developer and services company. Kinship's flagship product, EXACT, is a revolutionary system that allows users to quickly construct reusable programs for data extraction, data transformation, statistical reporting and electronic publishing.
buyer: PRA International (PRAH:$1,698.48)
PRA International conducts clinical trials across all therapeutic areas in more than 80 countries and provides services in all phases of clinical development through its 40 global offices. "
 target: Kinship Technologies Pvt. Ltd.
Kinship Technologies is a leading, global provider of innovative high-quality software products and services that enhance, optimize and accelerate the drug development process from source to submission through integration, automation and effective application of advanced technology solutions.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 8/5/2009 via PR Newswire

OmniComm Systems, Inc., purchased EDC Assets from Logos Technologies

See 294 Comparable Transactions
synopsis: OmniComm Systems, Inc., a leader in integrated electronic data capture (EDC) solutions for clinical trials announced that the company has acquired the EDC assets of UK based, clinical software provider, Logos Technologies, Ltd.
buyer: OmniComm Systems, Inc. (OTCPK:OMCM:$24.62)
OmniComm Systems, Inc. provides customer-driven Internet solutions to pharmaceutical, biotechnology, research and medical device organizations that conduct life changing clinical trial research. "
 seller: Logos Technologies
Logos Technologies is one of the early pioneers in providing world class solutions to pharmaceutical, contract research organisations and biotechnology companies with electronic data capture (EDC) and clinical management solutions needed to accelerate pharmaceutical research and development.
price ($mm)
$0.15
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 6/17/2009 via PR Newswire

Oracle Corporation, acquired Conformia Software, Inc.

See 308 Comparable Transactions
synopsis: Oracle announced that it has acquired the intellectual property assets of Conformia Software. Conformia's Product and Process Lifecycle Management (PPLM) software has unique capabilities which Oracle plans to integrate into their Agile PLM solution to offer an end-to-end solution for managing drug development, packaging and commercialization.
buyer: Oracle Corporation (ORCL:$39,766.00)
Oracle is the world's largest enterprise software company. The company is a leading provider of systems software, including database management, application development, and application server software. "
 target: Conformia Software, Inc.
Conformia Software, Inc. offers product/process lifecycle management solutions for the pharmaceutical and life sciences, biotech, and other process manufacturing organizations.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 11/20/2019 via BNC Analysis

Monterro, acquired Viedoc

See 182 Comparable Transactions
synopsis: Monterro, the leading B2B software investor in the Nordics, has acquired a majority stake in Viedoc, a modern and sophisticated electronic data capture (EDC) system. Viedoc enables researchers to gather and evaluate clinical trial data more efficiently.
buyer: Monterro
Sweden-based Monterro is the leading B2B software investor in the Nordics, with a mission to turn software companies into market leaders. With operational experience from successfully developing and running companies, Monterro actively supports its portfolio companies in all aspects of growth. "
 target: Viedoc
Viedoc is a modern and sophisticated electronic data capture (EDC) system. Viedoc enables researchers to gather and evaluate clinical trial data more efficiently. Their powerful EDC system has been used in over 2000 trials in more than 75 countries in all therapeutic areas and clinical phases.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 10/24/2019 via BNC Analysis

TrialScope, acquired Clinical Trial Connect, LLC

See 178 Comparable Transactions
synopsis: TrialScope has acquired Clinical Trial Connect, a platform used by disease foundations and advocacy groups that connects their community members to relevant clinical trials. As part of the acquisition, founder Mike Wenger will share his technological expertise as part of the TrialScope team.
buyer: TrialScope
TrialScope is the global leader in clinical trial transparency and compliance. TrialScope's tools and systems enable their customers to improve their clinical trial process, mitigate registry and lifecycle risk, and ultimately achieve greater business success. "
 target: Clinical Trial Connect, LLC
Clinical Trial Connect is a platform used by disease foundations and advocacy groups that connects their community members to relevant clinical trials. Clinical Trial Connect was founded by Mike Wenger, who developed his own algorithm for matching patients to clinical trials.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 8/28/2019 via BNC Analysis

JLL Partners, Water Street Healthcare Partners, acquired THREAD Research

See 717 Comparable Transactions
synopsis: Water Street Healthcare Partners and JLL Partners have acquired Orange County, California-based THREAD, a provider of technology that enables virtual research approaches to modernize clinical studies and registries.
buyer: JLL Partners
buyer: Water Street Healthcare Partners
JLL Partners is a middle-market private equity firm with a 30-year track record of building and transforming businesses. Water Street is a strategic investor focused exclusively on healthcare. The firm has a strong record of building market-leading companies across key growth sectors in healthcare. "
 target: THREAD Research
THREAD is a virtual research platform used by biopharma, CROs, non-profit researchers, and life science organizations to capture global clinical study data in between, as well as during and instead of clinic visits.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 7/17/2019 via GlobeNewswire

Anju Software, will acquire OmniComm Systems, Inc.

See 465 Comparable Transactions
synopsis: Anju Software, a leading provider of comprehensive software solutions to the life sciences industry, will be acquiring OmniComm, a healthcare technology company that provides web-based electronic data capture and eClinical solutions and related value-added services.
buyer parent: ABRY Partners, LLC
buyer: Anju Software
Anju Software, Inc. is a leading provider of comprehensive software solutions to the life sciences industry that provides an integrated platform spanning clinical operations, medical affairs, and commercial divisions, including integrated data intelligence. "
 target: OmniComm Systems, Inc. (OTCPK:OMCM:$24.62)
OmniComm is a healthcare technology company that provides web-based electronic data capture and eClinical solutions and related value-added services to pharmaceutical and biotech companies, contract research organizations, and other clinical trial sponsors.
price ($mm)[EV]
$72 [$81]
rev ($mm)
$25
EBITDA ($mm)
$2
EV / rev
3.4x
EV / EBITDA
46.2x
announced 6/12/2019 via BusinessWire

Dassault Systemes, will acquire Medidata

See 233 Comparable Transactions
synopsis: Dassault Systèmes, a provider of solutions that transform the way products are designed, provided and supported, will be acquiring Medidata, a provider of a platform for clinical development, commercial, and real-world data.
buyer: Dassault Systemes (ENXTPA:DSY:$4,387.64)
Based in France, Dassault Systèmes provides clients with virtual universes to imagine sustainable innovations. Its solutions transform the way products are designed, produced, and supported. They foster social innovation, expanding possibilities for the virtual world to improve the real world. "
 target: Medidata (MDSO:$660.00)
Medidata is leading the digital transformation of life science, with a platform for clinical development, commercial, and real-world data. Powered by artificial intelligence, Medidata helps accelerate value, minimize risk and optimize outcomes.
price ($mm)[EV]
$5,825 [$5,822]
rev ($mm)
$660
EBITDA ($mm)
$81
EV / rev
8.8x
EV / EBITDA
72.2x
closed 4/10/2019 via BNC Analysis

TriNetX, acquired Custodix N.V.

See 256 Comparable Transactions
synopsis: TriNetX has acquired Custodix, a Belgian-based provider of clinical trial patient recruitment solutions. TriNetX is a global health research network that has revolutionised clinical research. Custodix is a provider of clinical trial patient recruitment solutions offering a range of solutions for ensuring compliance.
buyer: TriNetX
TriNetX is the global health research network enabling healthcare organizations, biopharma and CROs to collaborate, enhance trial design, accelerate recruitment and bring new therapies to market faster. "
 target: Custodix N.V.
Custodix is a Belgian provider of clinical trial patient recruitment solutions offering a range of solutions for ensuring compliance with European and US data protection legislation and security best practices.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 10/17/2018 via Company Press Release

Oracle Corporation, will acquire GoBalto

See 178 Comparable Transactions
synopsis: Oracle announced that it has entered into an agreement to acquire goBalto, which delivers leading cloud solutions to accelerate clinical trials by streamlining and automating the selection and set up of the best performing clinical research sites to conduct trials.
buyer: Oracle Corporation (ORCL:$39,766.00)
Oracle is a computer technology corporation developing and marketing computer hardware systems and enterprise software products. By eliminating complexity and simplifying IT, Oracle enables its customers to accelerate innovation and create added value for their customers. "
 target: GoBalto
goBalto, Inc. is an award winning, venture backed group of industry veterans that creates simple, focused software for the global drug trial industry. Its products offer drug trial sponsors and clinical research organizations the fastest, easiest possible way to start clinical studies on the web.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 7/18/2018 via PR Newswire

Genstar Capital LLC, acquired CRF Health

See 294 Comparable Transactions
synopsis: Genstar Capital, a leading investor in healthcare technology and services companies, is pleased to announce the acquisition of CRF Health, a global provider of eCOA and eConsent solutions for the life sciences industry. CRF Health's eSource solutions improve trial engagement by making the patient the center of the clinical trial process.
buyer: Genstar Capital LLC
Genstar Capital is a leading private equity firm that has been actively investing in high quality companies for more than 25 years. Based in San Francisco, Genstar works in partnership with its management teams to transform its portfolio companies into industry-leading businesses. "
 target parent: Vitruvian Partners LLP
target: CRF Health
CRF Health is the leading provider of patient-centered eSource technology solutions for the life sciences industry. CRF Health's TrialMax® platform consistently demonstrates the industry's highest data accuracy, patient and site compliance, and patient retention.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 3/21/2018 via BusinessWire

Anju Software, acquired Sylogent

See 178 Comparable Transactions
synopsis: Anju Software Inc., a life sciences software platform backed by Providence Equity Partners, has acquired Sylogent. Sylogent delivers cloud based state of the art software solutions and business services to the pharmaceutical industry focused specifically on the information required to bring a product to market.
buyer parent: Providence Equity Partners Inc.
buyer: Anju Software
Anju Software is a life sciences enterprise software platform focused on delivering exceptional business application solutions. Anju was founded by professionals with deep software domain expertise and a track record of building software platforms through strategic acquisitions and organic growth. "
 target: Sylogent
Sylogent delivers software and business services to the pharmaceutical industry focused specifically on the information required to bring a product to market. They ensure the timely completion of critical information, maximize compliance goals and reduce risk management liability.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 10/24/2017 via PR Newswire

Bracket Global, acquired mProve Health

See 547 Comparable Transactions
synopsis: Bracket, a leading clinical trial technology and specialty services provider, announced the strategic acquisition of mProve Health Inc., a leading provider of mobile technologies for life science companies. mProve Health offers regulatory compliant mobile solutions for patient recruitment and electronic clinical outcome assessments.
buyer parent: Genstar Capital LLC
buyer: Bracket Global
Bracket is a clinical trial technology and specialty services provider dedicated to helping biopharmaceutical sponsors and contract research organizations increase the power of their clinical research data by leveraging core competencies in Science, Technology, and Service. "
 target: mProve Health
mProve Health is a leading provider of mobile technologies for life science companies, helping them connect better with patients. The company offers industry-grade, regulatory compliant mobile solutions for patient recruitment, patient engagement, and electronic clinical outcome assessments.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 8/9/2017 via Company Press Release

PRA Health Sciences, acquired Parallel 6

See 178 Comparable Transactions
synopsis: HCAP Partners, a California-based mezzanine debt and private equity firm, announced that it has exited its investment in Parallel 6, Inc. (“P6”), a mobile clinical (“mClinical”) SaaS platform designed to recruit, enroll, engage and manage patients in clinical trials. P6 was sold to PRA Health Sciences, Inc.
buyer parent: Kohlberg Kravis Roberts & Co.
buyer: PRA Health Sciences (PRAH:$1,698.48)
PRA Health Sciences, Inc. is one of the world’s leading global CROs by revenue, providing outsourced clinical development services to the biotechnology and pharmaceutical industries. Since 2000, PRA has participated in approximately 3,500 clinical trials worldwide. "
 target parent: HCAP Partners
target: Parallel 6
Parallel 6’s technology digitally enrolls, engages and manages patients using mobile endpoints. Sponsors and clinical research organizations can connect directly with and manage patients anywhere in the world, seamlessly integrating into their daily lives.
price ($mm)
$40
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 7/31/2017 via BusinessWire

Anju Software, acquired ClinPlus

See 294 Comparable Transactions
synopsis: Anju Software Inc., a life sciences software platform backed by Providence Equity Partners, has acquired the assets of ClinPlus, a division of DZS Software Solutions, Inc. ClinPlus has a full suite of products used for the performance of clinical trials including EDC, IWRS, CTMS, eTMF, Data Management, Coding and SAS Reporting.
buyer parent: Providence Equity Partners Inc.
buyer: Anju Software
Anju Software is a life sciences enterprise software platform focused on delivering exceptional business application solutions with outstanding customer support. Anju was founded by a group of operating and investment professionals with deep software domain expertise. "
 target parent: DZS Software Solutions, Inc.
target: ClinPlus
ClinPlus, a division of DZS Software Solutions, Inc., has a full suite of products used for the performance of clinical trials including EDC, IWRS, CTMS, eTMF, Data Management, Coding and SAS Reporting.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 3/28/2017 via PR Newswire

Genstar Capital LLC, acquired Bracket Global

See 294 Comparable Transactions
synopsis: Genstar Capital, a middle-market private equity firm focused on investments in targeted segments of the healthcare, financial services, software, and industrial technology industries, announced that it has acquired Bracket, a leading scientifically-driven clinical trial technology and specialty services provider, from Parthenon Capital Partners.
buyer: Genstar Capital LLC
Genstar Capital is a San Francisco-based private equity firm that invests in leading middle-market companies. For over 20 years, they have utilized their deep industry knowledge and extensive executive networks to create value at their companies. "
 target parent: Parthenon Capital Partners
target: Bracket Global
Bracket is a specialty services provider dedicated to helping pharmaceutical sponsors and contract research organizations (CROs) achieve greater certainty and accurate outcomes in their clinical trials.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 11/16/2016 via BNC Analysis

DrugDev, acquired SecureConsent

See 178 Comparable Transactions
synopsis: DrugDev has acquired SecureConsent, a developer of mobile e-consent software. SecureConsent replaces the paper methods that have historically been used to secure informed consent from patients participating in drug studies with an e-consent method that uses tablets and other mobile devices.
buyer: DrugDev
DrugDev streamlines engagement among sponsors, CROs and doctors to advance the common goal of doing more trials. Through the creation of global, standardized processes DrugDev is consistently and efficiently transforming the way drug developers identify, engage and pay investigators. "
 target: SecureConsent
The software products developed by Secure Consent replace the paper methods that have historically been used to secure informed consent from patients participating in drug studies with an e-consent method that uses tablets and other mobile devices.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 3/18/2016 via BNC Analysis

PRA Health Sciences, acquired Nextrials, Inc.

See 294 Comparable Transactions
synopsis: PRA Health Sciences acquired all of the outstanding shares of Nextrials, Inc., a developer of web-based software which integrates electronic health records with clinical trials. Nextrials is an innovative, award-winning, leader in web-based software solutions for the clinical research industry.
buyer parent: Kohlberg Kravis Roberts & Co.
buyer: PRA Health Sciences (PRAH:$1,698.48)
At PRA Health Sciences, providing innovative solutions for their clients is what they do. They strive to move drug discovery forward, to help them develop life-saving and life- improving drugs. "
 target: Nextrials, Inc.
Nextrials is an innovative, award-winning, leader in web-based software solutions for the clinical research industry. Prism®, the Company’s clinical trial management software, brings together sophisticated trial management and electronic data capture (“EDC”) in a single package.
price ($mm)
$4.70
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
Pages:  

Like Leadscope, Inc.


read more

Leadscope, Inc.

Quantitative Medicine

Adorial

Molegro

Bio-G

Simcyp Limited

Pharsight Corporation

Spectral Genomics, Inc.

Lixoft

Pirana Software

DILIsym Services, Inc.

Aureus Sciences

Cognigen Corporation

Tessella Ltd.

Archimedes, Inc.

i3 Analytics

Waban Software

Sunergia Group, Inc.

Lincoln Technologies, Inc.

SimBioSys Inc.

Pages:  
read more

Leadscope, Inc.

read more

Leadscope, Inc.

Notocord

Samarind Limited

Logos Technologies

read more

Leadscope, Inc.

Notocord

Kinship Technologies Pvt. Ltd.

Logos Technologies

Conformia Software, Inc.

Viedoc

Clinical Trial Connect, LLC

THREAD Research

OmniComm Systems, Inc.

Medidata

Custodix N.V.

GoBalto

CRF Health

Sylogent

mProve Health

Parallel 6

ClinPlus

Bracket Global

SecureConsent

Nextrials, Inc.

Pages:  
Geography
Matching Companies
Ticker: SLP
 
 
 
 
 
 
 
 
Simulations Plus, Inc.
Simulations Plus, Inc.
Simulations Plus, Inc. is a premier developer of groundbreaking drug discovery and development simulation and modeling software that is licensed to and used in the conduct of drug research by major pharmaceutical, biotechnology, agrochemical, and food industry companies worldwide.
year
2019
rev ($mm)
$35.84
EBITDA ($mm)
$12.38
EBIT ($mm)
$11.28
Net Income ($mm)
$9.11
Employees
109
  • drill down
  • watch
Ticker: POAI
 
 
 
 
 
 
 
 
Predictive Oncology Inc.
Predictive Oncology Inc.
Predictive Oncology Inc. is a knowledge-driven company focused on applying artificial intelligence to personalized medicine and drug discovery. Predictive Oncology operates through five segments which contain four subsidiaries; Helomics, TumorGenesis, Skyline Medical and Skyline Europe.
year
2019
rev ($mm)
$1.38
EBITDA ($mm)
($13.26)
EBIT ($mm)
($13.71)
Net Income ($mm)
Employees
24
  • drill down
  • watch
Ticker: DATA
 
 
 
 
 
 
 
 
DATATRAK International, Inc.
DATATRAK International, Inc.
DATATRAK International, Inc. is a worldwide ASP for the EDC industry. The Company provides a suite of software products supporting the use of DATATRAK EDC(TM) and related services to the pharmaceutical, biotechnology, and medical device industries.
year
2012
rev ($mm)
$9.72
EBITDA ($mm)
($1.37)
EBIT ($mm)
($1.53)
Net Income ($mm)
Employees
  • drill down
  • watch
Ticker: AIM:INS
 
 
 
 
 
 
 
 
Instem
Instem
Instem is a leading supplier of IT applications to the early development healthcare market delivering compelling solutions for data collection, management and analysis across the R&D continuum. Instem applications are in use by customers worldwide.
year
2019
rev ($mm)
$30.83
EBITDA ($mm)
$4.12
EBIT ($mm)
$3.15
Net Income ($mm)
$2.27
Employees
238
  • drill down
  • watch
Ticker: OTCPK:OMCM
 
 
 
 
 
 
 
 
OmniComm Systems, Inc.
OmniComm Systems, Inc.
OmniComm Systems, Inc. is a leading strategic software solutions provider to the life sciences industry. OmniComm is dedicated to helping the world’s pharmaceutical, biotechnology, diagnostic and device firms, and academic medical centers maximize the value of their clinical research investments.
year
2019
rev ($mm)
$24.62
EBITDA ($mm)
$1.80
EBIT ($mm)
$1.31
Net Income ($mm)
$1.83
Employees
175
  • drill down
  • watch
Ticker: OMCL
 
 
 
 
 
 
 
 
Omnicell, Inc.
Omnicell, Inc.
Omnicell is a leading supplier of comprehensive automation and business analytics software for patient-centric medication and supply management across the entire health care continuum—from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home.
year
2016
rev ($mm)
$692.62
EBITDA ($mm)
$62.94
EBIT ($mm)
$16.58
Net Income ($mm)
$0.60
Employees
2444
  • drill down
  • watch
Ticker: TRHC
 
 
 
 
 
 
 
 
Tabula Rasa Healthcare
Tabula Rasa Healthcare
Tabula Rasa HealthCare (TRHC) is a leader in providing patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations, lower healthcare costs and manage risk.
year
2018
rev ($mm)
$204.27
EBITDA ($mm)
$16.27
EBIT ($mm)
$1.63
Net Income ($mm)
Employees
952
  • drill down
  • watch
Ticker: ZMD
 
 
 
 
 
 
 
 
ZoomMed Inc.
ZoomMed Inc.
Zoommed Inc. develops and markets various computer applications for healthcare professionals in Canada. The company builds and operates the ZoomMed Communication Network, a clinical interoperable information exchange network between physicians and various other stakeholders of the healthcare sector.
year
2014
rev ($mm)
$6.08
EBITDA ($mm)
$2.65
EBIT ($mm)
$2.78
Net Income ($mm)
Employees
40
  • drill down
  • watch
Ticker: ASX:MDR
 
 
 
 
 
 
 
 
MedAdvisor Limited
MedAdvisor Limited
MedAdvisor is a world class medication management platform focused on addressing the gap and burden of medication adherence. The highly automated Australian software system connects patients to their local pharmacy, providing them with real time access to their personal medication records.
year
2016
rev ($mm)
$1.05
EBITDA ($mm)
($2.13)
EBIT ($mm)
($2.15)
Net Income ($mm)
Employees
  • drill down
  • watch
Ticker: AIM:INS
 
 
 
 
 
 
 
 
Instem
Instem
Instem is a leading supplier of IT applications to the early development healthcare market delivering compelling solutions for data collection, management and analysis across the R&D continuum. Instem applications are in use by customers worldwide.
year
2019
rev ($mm)
$30.83
EBITDA ($mm)
$4.12
EBIT ($mm)
$3.15
Net Income ($mm)
$2.27
Employees
238
  • drill down
  • watch
Ticker: OTCPK:OMCM
 
 
 
 
 
 
 
 
OmniComm Systems, Inc.
OmniComm Systems, Inc.
OmniComm Systems, Inc. is a leading strategic software solutions provider to the life sciences industry. OmniComm is dedicated to helping the world’s pharmaceutical, biotechnology, diagnostic and device firms, and academic medical centers maximize the value of their clinical research investments.
year
2019
rev ($mm)
$24.62
EBITDA ($mm)
$1.80
EBIT ($mm)
$1.31
Net Income ($mm)
$1.83
Employees
175
  • drill down
  • watch
Ticker: DATA
 
 
 
 
 
 
 
 
DATATRAK International, Inc.
DATATRAK International, Inc.
DATATRAK International, Inc. is a worldwide ASP for the EDC industry. The Company provides a suite of software products supporting the use of DATATRAK EDC(TM) and related services to the pharmaceutical, biotechnology, and medical device industries.
year
2012
rev ($mm)
$9.72
EBITDA ($mm)
($1.37)
EBIT ($mm)
($1.53)
Net Income ($mm)
Employees
  • drill down
  • watch
Ticker: SLP
 
 
 
 
 
 
 
 
Simulations Plus, Inc.
Simulations Plus, Inc.
Simulations Plus, Inc. is a premier developer of groundbreaking drug discovery and development simulation and modeling software that is licensed to and used in the conduct of drug research by major pharmaceutical, biotechnology, agrochemical, and food industry companies worldwide.
year
2019
rev ($mm)
$35.84
EBITDA ($mm)
$12.38
EBIT ($mm)
$11.28
Net Income ($mm)
$9.11
Employees
109
  • drill down
  • watch
Ticker: POAI
 
 
 
 
 
 
 
 
Predictive Oncology Inc.
Predictive Oncology Inc.
Predictive Oncology Inc. is a knowledge-driven company focused on applying artificial intelligence to personalized medicine and drug discovery. Predictive Oncology operates through five segments which contain four subsidiaries; Helomics, TumorGenesis, Skyline Medical and Skyline Europe.
year
2019
rev ($mm)
$1.38
EBITDA ($mm)
($13.26)
EBIT ($mm)
($13.71)
Net Income ($mm)
Employees
24
  • drill down
  • watch
Ticker: OMCL
 
 
 
 
 
 
 
 
Omnicell, Inc.
Omnicell, Inc.
Omnicell is a leading supplier of comprehensive automation and business analytics software for patient-centric medication and supply management across the entire health care continuum—from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home.
year
2016
rev ($mm)
$692.62
EBITDA ($mm)
$62.94
EBIT ($mm)
$16.58
Net Income ($mm)
$0.60
Employees
2444
  • drill down
  • watch
Ticker: TRHC
 
 
 
 
 
 
 
 
Tabula Rasa Healthcare
Tabula Rasa Healthcare
Tabula Rasa HealthCare (TRHC) is a leader in providing patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations, lower healthcare costs and manage risk.
year
2018
rev ($mm)
$204.27
EBITDA ($mm)
$16.27
EBIT ($mm)
$1.63
Net Income ($mm)
Employees
952
  • drill down
  • watch
Ticker: ZMD
 
 
 
 
 
 
 
 
ZoomMed Inc.
ZoomMed Inc.
Zoommed Inc. develops and markets various computer applications for healthcare professionals in Canada. The company builds and operates the ZoomMed Communication Network, a clinical interoperable information exchange network between physicians and various other stakeholders of the healthcare sector.
year
2014
rev ($mm)
$6.08
EBITDA ($mm)
$2.65
EBIT ($mm)
$2.78
Net Income ($mm)
Employees
40
  • drill down
  • watch
Ticker: ASX:MDR
 
 
 
 
 
 
 
 
MedAdvisor Limited
MedAdvisor Limited
MedAdvisor is a world class medication management platform focused on addressing the gap and burden of medication adherence. The highly automated Australian software system connects patients to their local pharmacy, providing them with real time access to their personal medication records.
year
2016
rev ($mm)
$1.05
EBITDA ($mm)
($2.13)
EBIT ($mm)
($2.15)
Net Income ($mm)
Employees
  • drill down
  • watch
Ticker: MRCY
 
 
 
 
 
 
 
 
Mercury Computer Systems, Inc.
Mercury Computer Systems, Inc.
Mercury Computer Systems is the leading supplier of high-performance digital signal and image processing systems. These embedded computer systems transform streams of sensor data to visual information in real time for analysis and interpretation.
year
2011
rev ($mm)
$228.71
EBITDA ($mm)
$33.90
EBIT ($mm)
$25.55
Net Income ($mm)
$18.44
Employees
602
  • drill down
  • watch
Ticker: SYPT
 
 
 
 
 
 
 
 
Scrypt, Inc.
Scrypt, Inc.
Since 1998, Austin-based Scrypt, Inc. has been creating elegant document productivity tools for healthcare that eliminate manual processes and paper to save time and money. Scrypt has more than 30,000 customers across all 50 states.
year
2009
rev ($mm)
$0.27
EBITDA ($mm)
($0.85)
EBIT ($mm)
($0.91)
Net Income ($mm)
Employees
7
  • drill down
  • watch
Ticker: CERN
 
 
 
 
 
 
 
 
Cerner Corporation
Cerner Corporation
Cerner's health information technologies connect people, information, and systems. Cerner solutions assist clinicians in making care decisions and enable organizations to manage the health of populations.
year
2020
rev ($mm)
$5,714.46
EBITDA ($mm)
$1,168.86
EBIT ($mm)
$707.10
Net Income ($mm)
$510.39
Employees
27400
  • drill down
  • watch
Ticker: 300253
 
 
 
 
 
 
 
 
Shanghai Kingstar Winning Software Co., Ltd.
Shanghai Kingstar Winning Software is principally engaged in the development of medical software, the provision of technology services and the distribution of hardware products. They primarily offer software, including hospital information systems and public health information management systems.
year
2015
rev ($mm)
$98.42
EBITDA ($mm)
$14.01
EBIT ($mm)
$12.72
Net Income ($mm)
$21.57
Employees
454
  • drill down
  • watch
Ticker: OM:RTC
 
 
 
 
 
 
 
 
Rethinking Care AB
Rethinking Care AB
Rethinking Care introduces a holistic concept in nursing & health, based on 3 interacting spheres of activity - "Software as a service", "Care as a service" & "Health as a service", based on a high level of competence in nursing & healthcare services as well as IT tools developed for health care.
year
2016
rev ($mm)
EBITDA ($mm)
EBIT ($mm)
Net Income ($mm)
Employees
  • drill down
  • watch
Ticker: INOV
 
 
 
 
 
 
 
 
Inovalon, Inc.
Inovalon, Inc.
Inovalon is a leading technology company that combines advanced cloud-based data analytics and data-driven intervention platforms to achieve meaningful insight and impact in clinical and quality outcomes, utilization, and financial performance across the healthcare landscape.
year
2017
rev ($mm)
$449.36
EBITDA ($mm)
$75.91
EBIT ($mm)
$27.16
Net Income ($mm)
$34.82
Employees
2119
  • drill down
  • watch